Difference between revisions of "Part:BBa K5023000:Design"

 
(→‎References)
Line 20: Line 20:
  
 
===References===
 
===References===
 +
GATIGNOL, A.; DURAND, H.; TIRABY, G. Bleomycin resistance conferred by a drug-binding protein. FEBS Letters, v. 230, n. 1-2, p. 171–175, 28 mar. 1988.
 +
 +
‌

Revision as of 19:01, 8 October 2023


Bleomycin Resistance Gene


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal PstI site found at 227
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal PstI site found at 227
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal PstI site found at 227
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal PstI site found at 227
    Illegal NgoMIV site found at 608
    Illegal NgoMIV site found at 669
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

This resistance to bleomycin gene has one rbcs intron. The insertion of an rbcs intron into the bleomycin resistance gene represents an innovative strategy for heterologous expression in Chlamydomonas reinhardtii. The rbcs gene encodes the enzyme ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO), which is essential for the carbon fixation process in photosynthesis. Introns, non-coding DNA sequences, play a crucial role in gene expression regulation and messenger RNA processing.

By inserting an rbcs intron into the bleomycin resistance gene, the aim is to enhance the gene's expression and stability in Chlamydomonas reinhardtii. This strategy may allow the alga to express the bleomycin resistance gene more efficiently, enabling its survival in the presence of the antibiotic. Additionally, the intron insertion may help prevent messenger RNA degradation and improve gene translation.

This approach holds significant potential for biotechnology and research in Chlamydomonas reinhardtii. By enhancing the heterologous expression of genes of interest, algal strains with desired characteristics can be developed, ranging from biofuel production to the synthesis of bioactive compounds.


Source

ATGGCCAAGCTGACCAGCGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGCGGTCGAGTTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCCGGGACGACGTGACCCTGTTCATCAGCGCGGTCCAGGACCAGGtgagcttgcggggttgcgagcaacactccagcaacgaacagtgcccaagtcaggaatctgcagtcagcctgggctttcggcggctttttcttgggcaaacagcttgcactcatgccagcgcggcttgtccagcctcacttgagctttccagctgctaccagccgggctatacgacagcgacagagccatagcgtggaatcacttatttgggttgccgaagtagcggtcggagcgtgagttcttggtcaagccgccccttatccggttcctgtccgtgtctttgtccctcgttcacccttcgcggcacccttcatccccttgcttgcaggACCAGGTGGTGCCGGACAACACCCTGGCCTGGGTGTGGGTGCGCGGCCTGGACGAGCTGTACGCCGAGTGGTCGGAGGTCGTGTCCACGAACTTCCGGGACGCCTCCGGGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGGGCGGGAGTTCGCCCTGCGCGACCCGGCCGGCAACTGCGTGCACTTCGTGGCCGAGGAGCAGGACGCCCCG

References

GATIGNOL, A.; DURAND, H.; TIRABY, G. Bleomycin resistance conferred by a drug-binding protein. FEBS Letters, v. 230, n. 1-2, p. 171–175, 28 mar. 1988.

‌